SFSIG
PDLI

San Francisco Sentry Investment Group’s PDL BioPharma, Inc. PDLI Stock Holding History

San Francisco Sentry Investment Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-353
Closed -$1K – 1121
2018
Q4 		$1K Buy
+353
New +$970 ﹤0.01% 972
2014
Q4 		– Sell
-2,000
Closed -$15K – 589
2014
Q3 		$15K Hold
2,000
– – 0.01% 428
2014
Q2 		$19K Hold
2,000
– – 0.01% 418
2014
Q1 		$17K Buy
+2,000
New +$17.1K 0.01% 467

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

San Francisco Sentry Investment Group's PDLI Position: Q1 2019 in Review

San Francisco Sentry Investment Group sold out of PDL BioPharma, Inc. (PDLI) in Q1 2019, closing a stake of 353 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in PDLI in Q1 2014 and held it in 4 quarters. The position peaked at $19K in Q2 2014. 157 funds tracked by Wall St. Rank hold PDLI as of Q1 2019.

  • San Francisco Sentry Investment Group reported no remaining PDL BioPharma, Inc. position as of Q1 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 353 PDL BioPharma, Inc. shares in Q1 2019, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in PDL BioPharma, Inc. in Q1 2014 and held it in 4 quarters.
  • San Francisco Sentry Investment Group's PDL BioPharma, Inc. position peaked at $19K in Q2 2014.
  • 157 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q1 2019, filed 8 May 2019.